- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02315235
The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy
The Efficacy and Safety of Peripheral Mobilized Mononuclear Cell-based Therapy in Patients With Diabetic Painful Neuropathy
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Diabetic painful neuropathy a prevalent, disabling disorder. Currently, the only effective treatments are glucose control and pain management. Diabetic neuropathy is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophic factors, these cells have been attempted for treating experimental diabetic neuropathy, and turned out to be effective for reversing various manifestations of experimental diabetic neuropathy.
However, stem-cell therapy was not proven in human study. Therefore, we will investigate the efficacy and safety of autologous peripheral blood stem cell injection in diabetic neuropathy.
Studietyp
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Seoul, Korea, Republiken av
- SeoulNUH
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- symptomatic diabetic neuropathy moderate pain more than 3 months Michigan Neuropathy Screening Instrument (MNSI) >3 3/day mean pain scale > NRS 4 Body weight >50 kg systolic blood pressure: 90-150 mmHg, Diastolic blood pressure <100 mmHg, Body temperature <37.5℃, Pulse rate: 50-100/min
Exclusion Criteria:
- other cause of neuropathy symptomatic peripheral vessel disease skin lesion or arthritis central neuronal disease drug addiction or abuse Aspartate aminotransferase or Alanine aminotransferase >1.5 times than upper normal limit range Creatinine clearance rate <60ml/min or dialysis Myocardial infarction, unstable angina or heart failure diagnosed in 3 months psychologic disorder pregnancy or lactation
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: control
The operator inject normal saline(control) to thirty site of the other side leg of active comparator.
The volume of one site injection is 0.5 ml.
The depth of needle injection would be 1.5cm.
|
Normal saline is injected in one leg of patient.
|
Aktiv komparator: stem cell (mononuclear cell)
The stem cell (mononuclear cell) is injected to thirty site of one side leg in operating room after general anesthesia.
The volume of one site injection is 0.5 to 1.0 ml.
The depth of needle injection would be 1.5cm.
|
Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day. The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Changes in pain for a week after the procedure
Tidsram: baseline, 4 week, 12 week
|
The pain scale was calculate by Numeric rating scale (NRS).
We observe a change in NRS pain scores during the follow-up period.
|
baseline, 4 week, 12 week
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The evaluation of changes in the specific neuro-sensory system
Tidsram: baseline, 4 week, 12 week
|
The following tests was evaluated during the follow-up period.
The pain intensity was evaluated by short-form McGill Pain Questionnaire and by sleep disturbance pain score.
The quantitative change of sensory nerve was evaluated by quantitative sensory test (QST).
We measure serum neuron-specific enolase (NSE), glucose, insulin and c-peptide.
The amount of drug requirements will also assess at each follow-up period.
|
baseline, 4 week, 12 week
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The secondary effect of the procedure for the peripheral nerves and blood vessels
Tidsram: baseline, 12 week
|
Michigan neuropathy screening instrument (MNSI) is used for screening for diabetic peripheral neuropathy.
Changes in patient's mood is assessed by the Beck Depression Inventory (BDI) system.
Electrophysiological tests are used in the evaluation of nerve conduct velocity.
Skin punch biopsy is used to evaluate the density of epidermal nerve fibers.
Improvement of blood flow in the peripheral veins is evaluated by ankle brachial index (ABI), pulse wave velocity (PWV) and digital arterial plethysmography.
We measure serum glucose, insulin ant c-peptide.
The amount of drug requirements will also assess at each follow-up period.
|
baseline, 12 week
|
Samarbetspartners och utredare
Utredare
- Studiestol: Hye Seung Jung, Ph.D., Seoul Nation University Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- mononuclear cell-based therapy
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetisk neuropati
-
Fayoum UniversityCairo UniversityHar inte rekryterat ännuSGLT2i Kideny Protection Against Contrast in Diabetic Kidney
-
Ocuphire Pharma, Inc.AvslutadDiabetisk retinopati | Diabetiskt makulaödem | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferativ diabetisk retinopatiFörenta staterna
-
Assiut UniversityOkändom Vitreomacular Interface Abnormalities in Diabetic Retinopathy
-
Association for Innovation and Biomedical Research...Fundação para a Ciência e a TecnologiaAvslutadNPDR - Non Proliferative Diabetic RetinopathyPortugal
-
Association for Innovation and Biomedical Research...European Vision Institute Clinical Research NetworkAktiv, inte rekryterandeDiabetes mellitus, typ 2 | Näthinnesjukdom | NPDR - Non Proliferative Diabetic RetinopathyFrankrike, Italien, Portugal
Kliniska prövningar på Normal saline
-
Vanderbilt University Medical CenterAktiv, inte rekryterandePosturalt takykardisyndromFörenta staterna
-
Nicklaus Children's Hospital f/k/a Miami Children...AvslutadAfibrinogenemi | Hypofibrinogenemi | BlödningsstörningarFörenta staterna
-
St George's, University of LondonAvslutad
-
Qassim UniversityAvslutadApikal parodontit | Postoperativ smärta | TandmassanekroserSaudiarabien
-
Smigel, Liza, M.D.AvslutadRyggsmärta Nedre delen av ryggen KroniskFörenta staterna
-
Sorrento Therapeutics, Inc.AvslutadArtros, knä | Smärta, knäFörenta staterna
-
Shanghai Jiao Tong University School of MedicineWest China Hospital; Guangzhou General Hospital of Guangzhou Military Command och andra samarbetspartnersOkändHud; Deformitet, på grund av ärrKina
-
Ahmed SaadHawaa Fertility CenterHar inte rekryterat ännuFör tidig ovariesviktEgypten
-
Shanghai Jiao Tong University School of MedicineOkänd
-
Nihon UniversityIwate Medical University; Tokyo Medical and Dental University; Hiroshima... och andra samarbetspartnersAvslutad